Hemophilia A (HA), a common inherited bleeding disorder in humans, is due to the deficiency or absence of the factor Vlll (FVIII) activity. The cloning of the FVlll gene has made molecular probes available for the characterization of the basic defect in this disease. In this study we describe six different mutations in the FVlll gene detected by DNA analysis of 100 HA patients of Italian descent. In two of them, with a severe clinical picture, we identified two novel deletions, one in the middle of the FVlll gene from exons 7 to 22 and the other encompassing the entire factor Vlll gene. Both of these patients produced antibodies to factor VIII. In a patient with mild HA we detected a duplication of exon 13, which is a rearrangement not yet described within the FVlll gene. A possible explanation for the mild phenotype in this patient is that the molecular defect results in the production of an unstable FVlll protein with residual EMOPHILIA A (HA), a common inherited bleeding H disease in humans, is caused by a deficiency of the clotting factor VI11 (FVIII:C). ' The clinical severity varies markedly and is closely correlated to plasma FVIII activity. After therapy with FVIII concentrates, approximately 15% of the patients produce high levels of antibodies (inhibitors) against FVIII.
The disease is inherited as an X-linked recessive trait and, according to the Haldane hypothesis,* one third of the cases result from a de novo mutation. The locus coding for FVIII has been assigned to the tip of the long arm of chromosome X (Xq28-qter) . 3 The FVIII gene has been cloned and sequenced:.' It is 186 kilobases (kb) in length, contains 25 introns and 26 exons, and the respective messenger R N A (mRNA) spans about 9 kb. The availability of molecular probes from the FVIII gene has allowed studies of the molecular bases of HA. Several 10% FVlll activity. Screening by Taq I restriction endonuclease detected three mutations that were further characterized by direct sequencing on amplified DNA a C-T substitution at codon 1960. in exon 18. converting the codon for arginine to a non-sense codon: and a G-A substitution at codon 2228 and 2326, in exons 24 and 26 respectively, resulting in the substitution of glutamine for arginine. All three of these mutations have been previously described. The non-sense mutation and the codon 2228 G-A mutation was found in patients with severe HA, while the codon 2326 G-A mutation was associated with a quite severe condition. These results confirm that the molecular bases of HA are very heterogeneous and provide further evidence that recurrent mutations are not uncommon in this system. 0 1990 by The American Society of Hematology.
mutations affecting the FVIII gene have been detected in patients with HA, including point mutations, gene deletions, and insertions of transposable elements.*-19 Point mutations were identified after digestion of the DNA with the restriction endonuclease TuqI, which recognizes the sequence TCGA. This sequence contains the CpG dinucleotide, which has been proposed as a hot-spot for mutation in mammals .20 In fact, the cytosine followed by guanosine is frequently methylated and has a high propensity to undergo spontaneous deamination, thus leading to a C-T transition. Using the restriction enzyme TaqI, seven CpG dinucleotides within exons in the FVIII gene can be investigated, and six of them have been found recurrently mutated in different unrelated
In this study we investigate the molecular basis of H A in several patients of Italian descent. Of 100 individuals tested, we detected two novel gene deletions, one of which encompasses the entire FVIII gene; and a duplication of exon 13, which is an undescribed rearrangement in the FVIII gene. We also characterized, by direct sequencing of genomic amplified DNA, three single nucleotide substitutions a t the TaqI sites of exons 18,24, and 26, which further supports the hypothesis that the CpG dinucleotide is a hot-spot for mutations in FVIII gene.
HA patients. 8-10. 12,13,17.18 
MATERIALS AND METHODS
We studied 100 unrelated patients of Italian descent with HA, 65% of whom were considered severe (FVIII activity less than 1% of normal) and 35% as moderate to mild (2% to 10% of normal). Approval was obtained from the Institutional Review Board for these studies. Patients (and/or volunteers) were informed that blood (and/or bone marrow or tissue) samples were obtained for research purposes, and that their privacy would be protected.
FVIII coagulant activity (VIII-C) was measured by a one-stage method." FVIII inhibitor activity was measured by the method of Kasper et Figure 1 shows the FVIII gene, the position of all the probes used for Southern blot analysis, and the oligonucleotides used for hybridization and amplification. Filters were first hybridized to: probe A (spanning from exon 1 to exon 14) , and probe B (spanning from exon 14 to exon 26), kindly provided by Chiron Corporation, Emeryville, CA (Fig 1) . Between the two probes there is a gap so they do not cover the middle part of the exon 14. Samples showing a variant restriction enzyme fragment pattern were rehybridized to smaller cDNA probes obtained by digesting probes A and B with different restriction enzymes (Fig 1): probe C (complementary to exons 1 through 7); probe D (exons 14 through 21); probe E (exons 13 and 14); probe F (exons 21 through 26); and probe G (exon 26). In addition, in some specific cases, other restriction endonucleases were used to better characterize the molecular defects.
It should be noted that (1) in some Southern blots the restriction fragment bands appear very faint due to the low amount of DNA used, and (2) because of the different length of the exons, hybridization with cDNA probes produces bands of different intensity in the autoradiographs. However, all the results were confirmed by repeating the same experiment several times. The genomic probe p625.8 (kindly provided by J. Gitschier, Howard Hughes Medical Institute, San Francisco, CA), a 3.15-kb EcoRI single copy fragment located in a region 30 kb from the 3' end of exon 26, was also used.
Oligonucleotide analysis. Two oligonucleotides 30 bases long, one complementary to the 5' end (5'-ATCAATGGCTATGTTTTT-GATAGTTTG-3') and the other complementary to the 3' end of exon 1 3 (5'-AGAAACTGTCTTCATGTCGATGGAAAACCC-3') (Fig l) , were synthesized using an automatic synthesizer (System 1 plus, Beckman Instruments, Inc, Palo Alto, CA). They were labeled by phosphorylation at the 5' end using T4 polynucleotide kinase (Bethesda Research Laboratories) and [y"P]-ATP (Amersham). The hybridization was performed directly on dried agarose gelsz9 at 65OC for 2 hours. After three 20-minute washings at room temperature and 2 to 3 minutes at 63OC in 6X saline sodium citrate (SSC) (1 x SSC = 8.75 g of sodium cloride and 4.4 g of sodium citrate per liter), the gels were subjected to autoradiography.
The mutations affecting the TuqI recognition site were characterized by direct sequencing of amplified DNA. To amplify the three DNA fragments containing 
Polymerase chain reaction (PCR).
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RESULTS
The strategy used in this study for screening 100 HA patients for the presence of gross structural rearrangements or simple nucleotide substitutions affecting the TuqI sites was based on the digestion of DNA samples with TuqI, SstI, and EcoRI restriction endonucleases (the FVIII restriction maps for these enzymes have been reported by others4**) and hybridization with probes A and B. By this procedure we detected an abnormal pattern in six patients in whom further analysis with more restriction endonucleases and specific probes was performed. The pertinent clinical features of these six patients are summarized in Table 1 .
Southern blotting of genomic DNA from this patient did not show any hybridization signal with either probe A or B, suggesting a deletion of the entire gene (Fig 2) . Hybridization of the BamHI-digested DNA to a 3.1-kb EcoRI single copy fragment (p.625.8). located 30 kb to the 3' Purienr H1.
of the FVIII gene, produced an abnormal fragment of about 5.4 kb that replaces the normal 3.5-kb fragment, indicating that the 3' breakpoint was within the region recognized by this probe (Fig 3) . This result was also confirmed by digesting the patient's DNA with EcoRI and Sstl and hybridizing with the same probe (data not shown, see map in Fig 3) . Using the p625.8 probe, the hybridization pattern of the patient's mother was found to be normal, indicating that the mutation arose de novo in the maternal germinal cells. The 5' breakpoint of this large deletion has not been exactly mapped. However, it has been ascertained that a region of IO kb from the 5' end of the gene is missing in our patient. In fact, a 1.3-kb (701.1) single copy probe 17 kb from the 5'of the FVIII gene failed to hybridize to the patient's DNA in several Southern blots (Susan Kenwrick, unpublished observations. September 1989).
DNA from patient H2, digested with TuqI and SstI and hybridized to probes A and B, showed the absence of the DNA fragments from exons 7 to 22 (Fig 4) . derived from introns 6 and 22 will help us define the exact location of the breakpoint within these introns.
DNA from patient H3 digested with SstI and hybridized to probe A showed a larger abnormal 23-kb fragment, which replaces the normal 20-kb fragment (Fig 2) containing intron 12, exon 13, intron 13, and part of exon 14. To better define the molecular lesion, the patient's DNA was digested with EcoRI or Hind11 and hybridized to probe E, which detects exon 13 and part of exon 14. A 16.5-kb EcoRI fragment replaced the normal 13-kb fragment containing exon 13 and intron 13, and an extra Hind 111 2.2-kb fragmenr was detected in addition to the 4.2-and 3.8-kb normal fragments (Fig 5a) .
To further characterize the molecular defect, we synthetized two oligonucleotide probes (5' and 3' oligo), 30 nucleotides (nts) in length, complementary to the DNA sequences at the 5' end 3' end of exon 13, respectively. Both of these
Patient H3.
oligonucleotide probes hybridized to the normal 3.8-kb as well as to the abnormal 2.2-kb Hind11 fragment (Fig 5b) . This suggested the presence of a duplication of the entire exon 13 either in intron 12 or intron 13 (Fig 5c) . In this patient, DDAVP challenge resulted in a rapid (at 15') and marked increase of FVIlI activity on the order of 10 times the basal level (lo%), followed by a rapid decrease to 50% of the basal level after 5 hours.
Restriction endonuclease analysis of the patient's DNA, digested with TuqI and hybridized to probe B, showed an abnormal 5.0-kb fragment and the absence of the normal 2.2-kb fragment that contains exons 18 and 19 of FVIII gene (Fig 6a) . Hybridization to probe D (exons 14 through 21) again showed the abnormal 5.0-kb fragment replacing the normal 2.8-(containing exons 15 through 18) and 2.2-kb fragments (data not shown). These results indicate that the mutation in patient H4 removed the TuqI recognition site in exon 18 (Fig 6b) . Direct genomic sequencing of the 180-bp amplified DNA containing the entire exon 18 detected a single nucleotide substitution, C-T. in the TuqI recognition site. This produced the non-sense codon TGA at codon 1960 in place of the normal CGA, which codes for arginine (Fig 6c) .
Analysis of TuqI-digested patient's DNA hybridized to probe B showed a new 4.2-kb fragment and the lack of the normal 1.4-kb fragment (Fig 7a) . This finding, confirmed by hybridization with probe F. containing exons 21 through 26 (data not shown), localizes the altered Tuq I site in exon 24 (Fig 7b) . Direct genomic sequencing of the 148-bp amplified DNA, which contains the entire exon 24, detected a C-T transition on the noncoding strand leading to a G-A transition at d o n 2228 of the coding strand in exon 24, which results in an Arg-Gln substitution (Fig 7c) . Hybridization of TuqI-digested patient's DNA to probe B showed an abnormal band of 12 kb (Fig 8a) .
Hybridization to probe G, which contains only exon 26 sequences, confirmed the presence of the abnormal 12-kb fragment and showed the absence of the normal 2.8-kb fragment that comprises a large part of exon 26 (data not shown).
The abnormal 12-kb fragment represents the sum of the normal 9.2-and 2.8-kb fragments, indicating that the mutation removed the TuqI site in exon 26 (Fig 8b) . The direct genomic sequencing of the 140-bp amplified DNA fragment containing the region surrounding the TuqI site in exon 26 showed a C-T transition on the noncoding strand leading to a G-A transition at codon 2326 of the coding strand, which results in an Arg -Gln substitution (Fig 8c) .
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DISCUSSION
In this study, by means of DNA analysis on 100 hemophilic Italian patients, six different molecular defects were detected, including two novel deletions, a duplication of exon 13, one non-sense, and two missense mutations. Of the two located approximately 30 kb to the 3' end of the gene. This is the largest deletion described so far in HA. In our series, the frequency of gene deletions is 2%. which is lower than the previous estimate of 5%" obtained by using the same methodology. In this connection, it is worth noting that the sample examined in this study is unbiased because no selection according to severity was made in the collection of the cases.
In accordance with other described FVIII deletion^,'^.'^.^^.'^ both defects reported herein are associated with a severe clinical picture and no detectable FVIII activity. Both patients with FVIII deletion showed the presence of high titer inhibitors to FVIII. These results are consistent with those of most report^,'^.'^ and contrast with only one." The presence of inhibitors has been detected previously in approximately one third of the patients with HA, but no correlation between their presence and the size or location of the deletion has been detected."
The duplication of exon 13 is a novel type of rearrangement in the FVIII gene and is most likely the cause of HA in this family. However, we cannot exclude that this mutation is a harmless polymorphism. But it should be noted that the exon 13 duplication has never been observed in 507 hemophilic X chromosomes analyzed so far.32 A similar mechanism of mutation has been described in the LDL receptor gene in a case of familial hypercholesterolemia and in the HPRT gene in a Lesch-Nyhan
In the case of familial hypercholesterolemia, a seven-exon duplication arose from an unequal crossing-over between homologous repetitive elements ( A h sequences) and resulted in an LDL receptor with reduced binding ability. In the Lesch-Nyhan patient the duplication of exons 2 and 3 in the HPRT gene produced a larger and stable mRNA, but no HPRT enzyme activity was detected. Oligonucleotide analysis showed that the 5' and the 3' end of exon 13 are present in the duplicated exon. The orientation of the duplicated exon 13 and addi- tional possible mutations within this region have not been ascertained in this study. Assuming that the duplicated exon 13 is normally oriented, from the analysis of published sequences of the FVlIl gene, duplicated sequences should be in frame with the normal FVIII coding sequences. However, cloning and sequencing analysis of the duplicated exon should be performed to prove this suggestion.
The molecular mechanism for the mild HA phenotype with 10% residual FVlll activity may be explained assuming either an inefficient splicing giving rise to a decreased level of a normal transcript, or the presence of an unstable larger FVIIl protein produced in normal quantity from an effinon-sense at codon 1960 in exon 18 and in the other two in an Arg-Gln substitution at codons 2228 and 2326 in exons 24 and 26, respectively. These three single nucleotide substitutions have already been detected in several other patients with HA of different ethnic origin who are presumably not related to our patients. These results further support the hypothesis that the CpG dinucleotide is a hot-spot for mutations." From the analysis of several gene systems, it has been estimated that the dinucleotide CpG within coding sequences of human genes is approximately 42 times more mutable than predicted on the basis of random m~tation.~'.'~ The mutations at the TuqI site described herein are most ciently spliced elongated mRNA.
The increase from about 10% to 100% FVIII activity detected 15 minutes after DDAVP administration and the FVlll half-life (T,,2 = 5 hours) indicates that the most likely molecular mechanism for the low FVllI activity may be the high instability of the FVllI protein. This mechanism is supported by the fact that, in our experience, DDAVP challenge in mild HA patients results in an increase of the FVlll activity markedly lower than in our patient, but with a prolonged half-life in the range of 7.5 to 11.6 hours instead of likely the cause of HA, but we cannot exclude the possibility that they are harmless polymorphisms. The presence of additional mutations elsewhere in the large FVIII gene has not, in fact, been excluded, and such a mutation will obviously escape detection by our strategy. However, it is very unlikely that these mutations represent harmless DNA polymorphisms because they have not been detected in over 200 normal chromosomes examined by us.
The clinical picture in patients with the non-sense at codon 1960 and the Arg-Gln change at codon 2228 was severe in 5 hours, as in our patient. The analysis of the FVIII antigen level will be helpful to clarify our hypothesis.
Using the restriction enzyme TuqI, wedetected three point mutations affecting the CpG dinucleotide in the coding region of the FVlll gene, which in one case resulted in a accordance with previous reports.I2 However, the moderatesevere phenotype with 2% of normal FVIII activity in the patient with the missense at codon 2326 in exon 26 contrasts with the mild clinical picture, with 9% of normal FVIII activity reported in another hemophiliac with the same molecular defect! We have no clear explanation for the contrasting phenotype presented by these two patients with an identical molecular lesion. One possibility accounting for this discrepancy could be the difference in the methodology of FVIII measurement, which was not reported for the case already described. However, we cannot rule out the possibility that the mutation detected at the TuqI site in exon 26 is a normal variant and that the lesion causing the mild hemophilia lies elsewhere in the FVIII gene, as discussed above. In this study we were able to define the molecular basis of those with deletions and non-sense mutations. Further studies are obviously necessary to establish whether the duplication of exon 13 and the missense mutations characterized are the cause of the HA phenotype. The percentage of the patients in whom we detected a mutation was 6%. and this is comparable with that (8% to 10%~)'~ reported by others using a similar approach. Application of new strategies to search for the presence of point mutations in the factor VI11 gene may extend our knowledge on the molecular bases of HA. This may ultimately lead to a better understanding of the general mechanism-producing mutations in humans. and Jane Gitschier for
